Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.62 |
| ▸ | JAK1 | P23458 | 11/20 | 0.62 |
| ▸ | JAK3 | P52333 | 5/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.62 |
| ▸ | PAK4 | O96013 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.62 |
| ▸ | RET | P07949 | 3/20 | 0.62 |
| ▸ | LTK | P29376 | 3/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.62 |
| ▸ | CLK2 | P49760 | 3/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.62 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.62 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.62 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.62 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17858793 | 1.00 | JAK2 (0.62) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858698 | 1.00 | JAK2 (0.62) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858717 | 0.90 | JAK2 (0.60) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL19466614 | 0.87 | JAK2 (0.65) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858807 | 0.87 | JAK2 (0.65) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858805 | 0.87 | JAK2 (0.65) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858795 | 0.87 | JAK2 (0.65) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL21159072 | 0.87 | JAK2 (0.67) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL17858808 | 0.86 | JAK2 (0.62) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL19496432 | 0.86 | JAK2 (0.64) | JAK2JAK1JAK3DAPK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111018861-B | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3904356-A1 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3235819-B1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL AS JAK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| EP-3235819-B1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL AS JAK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020135401-A1 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | 正大天晴药业集团股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
| CN-111018861-A | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095805-A1 | PYRROLOPYRIMIDINE COMPOUND | 北京赛林泰医药技术有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10561657-B2 | Pyrrolopyrimidine compound | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.